“The next big thing” in diabetes: clinical progress on DPP-IV inhibitors-Reference-Cited by-同舟云学术

“The next big thing” in diabetes: clinical progress on DPP-IV inhibitors

Published:2006 Issue:8 Volume:67 Page:627-642
ISSN:0272-4391
Container-title:Drug Development Research
language:en
Short-container-title:Drug Dev. Res.

Author:

von Geldern Thomas W.,Trevillyan James M.

Publisher

Wiley

Subject

Drug Discovery

Reference94 articles.

1. Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

2. Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes

3. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

4. , , , , . 2006. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM). American Diabetes Association 66th annual meeting, Washington, DC, poster abstract 1995-PO.

5. Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparing Unnatural Amino Acids;Reference Module in Chemistry, Molecular Sciences and Chemical Engineering;2022

2. Improved Synthesis of (R )-3-(t -Butoxycarbonylamino)-4-(2,4,5-trifluorophenyl)butanoic Acid as a Key Intermediate for the Synthesis of Sitagliptin;Bulletin of the Korean Chemical Society;2017-08

3. Cholinesterase Inhibitory Activities of Adamantyl-Based Derivatives and Their Molecular Docking Studies;Molecules;2017-06-17

4. DPP-4 Inhibitors;Comprehensive Medicinal Chemistry III;2017

5. Synthesis and Crystallographic Insight into the Structural Aspects of Some Novel Adamantane-Based Ester Derivatives;Molecules;2015-10-16